When Are Type 1 Diabetic Patients at Risk for Cardiovascular Disease?

被引：30
作者：
Orchard, Trevor J. [1 ]
Costacou, Tina [1 ]
机构：
[1] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA
来源：
CURRENT DIABETES REPORTS | 2010年 / 10卷 / 01期
关键词：
Type; 1; diabetes; Cardiovascular disease risk; Risk factors; Glycemia; Haptoglobin; CORONARY-ARTERY-DISEASE; MEDIATED OXIDATIVE STRESS; VITAMIN-E SUPPLEMENTATION; HAPTOGLOBIN GENOTYPE; PITTSBURGH EPIDEMIOLOGY; ENDOTHELIAL DYSFUNCTION; METABOLIC SYNDROME; INDIVIDUALS; MORTALITY; NEPHROPATHY;
D O I：
10.1007/s11892-009-0089-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This discussion of increased cardiovascular risk in patients with type 1 diabetes reviews recent data concerning glycemia and the role of glycemic control in type 1 diabetes, as well as observations of an association with haptoglobin genotype and coronary artery disease events. This genetic predisposition also leads to oxidative damage and appears to be associated with profound high-density lipoprotein dysfunction. This article also briefly discusses recent data on general cardiovascular risk factors and provides updated comments concerning the association of coronary artery disease with other diabetes complications, especially renal disease.
引用
收藏
页码：48 / 54
页数：7
相关论文
共 53 条
  • [1] Nutrition recommendations and interventions for diabetes - A position statement of the American Diabetes Association
    不详
    [J]. DIABETES CARE, 2008, 31 : S61 - S78
  • [2] Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo
    Asleh, R
    Guetta, J
    Kalet-Litman, S
    Miller-Lotan, R
    Levy, AP
    [J]. CIRCULATION RESEARCH, 2005, 96 (04) : 435 - 441
  • [3] Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease
    Asleh, R
    Marsh, S
    Shilkrut, M
    Binah, O
    Guetta, J
    Lejbkowicz, F
    Enav, B
    Shehadeh, N
    Kanter, Y
    Lache, O
    Cohen, O
    Levy, NS
    Levy, AP
    [J]. CIRCULATION RESEARCH, 2003, 92 (11) : 1193 - 1200
  • [4] Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype
    Asleh, Rabea
    Blum, Shany
    Kalet-Litman, Shiri
    Alshiek, Jonia
    Miller-Lotan, Rachel
    Asaf, Roy
    Rock, Wasseem
    Aviram, Michael
    Milman, Uzi
    Shapira, Chen
    Abassi, Zaid
    Levy, Andrew P.
    [J]. DIABETES, 2008, 57 (10) : 2794 - 2800
  • [5] In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease
    Asleh, Rabea
    Levy, Andrew
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2005, 1 (01) : 19 - 28
  • [6] Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years - Association with mortality and decline of glomerular filtration rate
    Astrup, Anne Sofie
    Tarnow, Lise
    Pietraszek, Lotte
    Schalkwijk, Casper G.
    Stehouwer, Coen D. A.
    Parving, Hans-Henrik
    Rossing, Peter
    [J]. DIABETES CARE, 2008, 31 (06) : 1170 - 1176
  • [7] Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes
    Averill, Michelle M.
    Bornfeldt, Karin E.
    [J]. CURRENT DIABETES REPORTS, 2009, 9 (01) : 18 - 25
  • [8] The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease
    Belch, Jill
    MacCuish, Angus
    Campbell, Iain
    Cobbe, Stuart
    Taylor, Roy
    Prescott, Robin
    Lee, Robert
    Bancroft, Jean
    MacEwan, Shirley
    Shepherd, James
    Macfarlane, Peter
    Morris, Andrew
    Jung, Roland
    Kelly, Christopher
    Connacher, Alan
    Peden, Norman
    Jamieson, Andrew
    Matthews, David
    Leese, Graeme
    McKnight, John
    O'Brien, Iain
    Semple, Colin
    Petrie, John
    Gordon, Derek
    Pringle, Stuart
    MacWalter, Ron
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 : a1840
  • [9] Bowman B.H., 1993, Hepatic Plasma Proteins. Ed, P159
  • [10] BOWMAN BH, 1982, ADV HUM GENET, V12, P189
123456